The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials.
Daniele RobestiLuigi NoceraFederico BelladelliJulianne G SchultzGiuseppe FallaraLaura MarandinoDaniele RaggiFrancesco MontorsiPavlos MsaouelAndrea NecchiAlberto MartiniPublished in: BJU international (2023)
The development of irAEs while receiving atezolizumab treatment was associated with improved oncological outcomes, namely overall and cancer-specific mortality, and progression free survival. These findings seem to not be substantially affected by administration of systemic corticosteroids.
Keyphrases
- papillary thyroid
- free survival
- squamous cell carcinoma
- locally advanced
- rectal cancer
- squamous cell
- small cell lung cancer
- prostate cancer
- cardiovascular events
- high grade
- case report
- metabolic syndrome
- big data
- radical prostatectomy
- phase ii study
- combination therapy
- robot assisted
- deep learning
- replacement therapy